Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Arch Ital Urol Androl ; 93(1): 68-70, 2021 Mar 19.
Artículo en Inglés | MEDLINE | ID: mdl-33754612

RESUMEN

Renal cell carcinoma (RCC) is known to cause metastasis to unusual sites, which can be both synchronous or metachronous. Thyroid gland is a rare site for metastasis. However, RCC is the most common primary neoplasm to metastasize to the Thyroid gland. Report of three cases and review of the literature.


Asunto(s)
Carcinoma de Células Renales/secundario , Neoplasias Renales/patología , Neoplasias de la Tiroides/secundario , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos
4.
World J Surg ; 40(11): 2790-2795, 2016 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-27334448

RESUMEN

BACKGROUND: In sigmoid cancer, both inferior mesenteric artery high or low ligations are accepted for curative purposes. Since inferior mesenteric artery ligation could compromise blood flow to the anastomosis, potentially increasing anastomotic leakage onset, real oncological benefits and possible disadvantages related to vascular transection level are still on debate. We introduce totally laparoscopic inferior mesenteric artery peeling technique to release from the concept of lymph nodal harvesting linked to arterial transection level. METHODS: Over a period of 24 months, 31 patients presenting with sigmoid cancer were submitted to laparoscopic sigmoidectomy associated with inferior mesenteric artery peeling. Data on intraoperative and postoperative outcomes have been prospectively collected. RESULTS: Mean operative time was 180 min (range 110-330 min); mean intraoperative blood loss was 60 ml (range 30-150 ml), and mean postoperative hospitalization was 6.2 days (range 4-11 days). Mean number of lymph node harvested was 16.7 (range 12-28). CONCLUSIONS: Given a proper selection of patients, laparoscopic sigmoidectomy comprehensive of sub-adventitial IMA skeletonization from its aortic origin could provide good oncological outcomes and recanalization rate. Further data are advocated to confirm these preliminary results.


Asunto(s)
Laparoscopía , Arteria Mesentérica Inferior/cirugía , Neoplasias del Colon Sigmoide/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Pérdida de Sangre Quirúrgica , Femenino , Humanos , Escisión del Ganglio Linfático , Masculino , Persona de Mediana Edad , Tempo Operativo , Proyectos Piloto , Estudios Prospectivos
5.
Melanoma Res ; 23(2): 96-101, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-23411479

RESUMEN

Several studies have reported an increase in vascular structures in malignant melanoma. Neovascularization can be enhanced by several factors. Among them, thymidine phosphorylase (TP) and cyclooxygenase-2 (COX-2) have been reported to play a role. The expressions of TP and COX-2 were evaluated trough immunohistochemistry in a series of 78 primary cutaneous melanomas diagnosed between 2000 and 2004. The expressions of TP and COX-2 through mRNA and western blot analysis were also evaluated in several melanoma cell lines. TP expression and COX-2 expression were considered positive in 25 cases (32%) and 22 cases (28.2%), respectively. TP-positive melanomas showed a lower mitotic rate (P=0.008), smaller thickness (P=0.01), and absence of lymphovascular invasion (P=0.04). COX-2-positive melanomas showed a higher mitotic rate (P=0.01) and higher thickness (P=0.03). COX-2 expression was associated with reduced disease-free survival (P=0.01). COX-2-positive cases showed a trend toward reduced survival, whereas TP was not correlated with overall survival. COX-2 expression was detected in four of 11 melanoma cell lines both by mRNA and by western blot analysis. Our data show that TP expression is associated with more favorable prognostic factors (such as thin melanoma, low mitotic count, and absence of lymphovascular invasion), whereas COX-2 expression is associated with poor prognostic factors (thicker melanoma and high mitotic count).


Asunto(s)
Ciclooxigenasa 2/biosíntesis , Melanoma/enzimología , Neoplasias Cutáneas/enzimología , Timidina Fosforilasa/biosíntesis , Adulto , Anciano , Anciano de 80 o más Años , Línea Celular Tumoral , Ciclooxigenasa 2/metabolismo , Supervivencia sin Enfermedad , Femenino , Humanos , Inmunohistoquímica , Masculino , Melanoma/patología , Persona de Mediana Edad , Pronóstico , Neoplasias Cutáneas/patología , Timidina Fosforilasa/metabolismo
6.
JSLS ; 17(4): 668-71, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24398216

RESUMEN

INTRODUCTION: Ovarian lymphoma is a rare entity, and hydronephrosis from lymphoma is even rarer. Most reports describe a laparoscopic approach to the disease, but we report a case of hydroureteronephrosis associated with ovarian lymphoma managed completely by miniinvasive techniques. CASE REPORT: A 51-year-old woman was referred to us for back pain and renal colic and computed tomography scan findings of right hydroureteronephrosis and a mass in the right mesorectum and uterosacral ligament. After magnetic resonance imaging was performed, the patient underwent laparoscopic adnexectomy and ureterolysis after ureteroscopy and stenting. Histology results showed diffuse B-cell lymphoma of the ovary occluding the ureter without infiltration. The patient has undergone 6 cycles of chemotherapy. DISCUSSION: This is the first report to describe ovarian lymphoma and hydroureteronephrosis managed completely by laparoscopic surgery and endoscopy. Frequency in clinical practice, differential diagnosis, and endoscopic approach are discussed. The advantages of a multidisciplinary endoscopic team are underlined.


Asunto(s)
Hidronefrosis/etiología , Linfoma de Células B/complicaciones , Neoplasias Ováricas/complicaciones , Neoplasias Ureterales/complicaciones , Terapia Combinada , Femenino , Humanos , Laparoscopía , Linfoma de Células B/tratamiento farmacológico , Linfoma de Células B/cirugía , Persona de Mediana Edad , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Ováricas/cirugía , Neoplasias Ureterales/tratamiento farmacológico , Neoplasias Ureterales/cirugía
7.
Diagn Pathol ; 6 Suppl 1: S25, 2011 Mar 30.
Artículo en Inglés | MEDLINE | ID: mdl-21489196

RESUMEN

BACKGROUND: In recent years, a number of technological advancements started to modify the long standing appearance and functionalities of traditional optical microscopes used in Pathology and other medical fields. In fact, at present many new tools for microscopical visualization exist that are based on digital imaging, robotization, and remote communication. Such tools are typically adopted in activities ranging from education to telediagnosis to remote consultation. Present paper describes the features of a basic digital microscope that has been tested to verify its performance for occasional remote consultation inside an international project between Italy and Slovenija, funded by Interreg initiative of the European Regional Development Fund. METHODS: The system is composed by a pair of digital microscopes (Leica DMD108, Leitz Microsystems, Wetzlar, Germany) associated to a high resolution videoconferencing systems (Tandberg 990, Lysaker, Norway). The systems are connected through the Internet. Sixty histology and cytology cases have been collaboratively diagnosed between two Pathology Institutes to verify the diagnostic performance of the system, regarding the image quality point of view as well as time needed for diagnosis. The system has also been tested for compatibility with standard videoconferencing software. RESULTS: No discrepancies between local and remote diagnoses have been identified, with diagnosis time reasonably close to typical microscope observation times. Time needed for most operations is not far from that needed on a traditional microscope, except for startup. CONCLUSIONS: The system can be considered usable as a standard microscope, and also for occasional remote consultations.


Asunto(s)
Microscopía/instrumentación , Consulta Remota/instrumentación , Telepatología/instrumentación , Redes de Comunicación de Computadores , Humanos , Italia , Microscopía/métodos , Consulta Remota/métodos , Eslovenia , Telepatología/métodos
9.
Int J Colorectal Dis ; 22(1): 7-13, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16538492

RESUMEN

INTRODUCTION: The object of neoadjuvant chemoradiotherapy regimens is a downstaging or downsizing of advanced rectal tumor to increase the rate of curative resection and reduce loco-regional failure. A reliable method of assessing response to adjuvant therapies is required to help standardize the assessments of new multimodality therapies. The purpose of this study was to evaluate the role played by tumor regression grading on the evaluation of pathological response to chemoradiotherapy, compared with both the predicting value of the clinical response to neoadjuvant therapy and pathologic response evaluation. METHODS: From 1994 to 2003, 58 patients with a primary diagnosis of rectal cancer were studied at our department and enrolled in a single center, not randomized study based on 5-week sessions of radiotherapy associated with a 30-day 5-fluorouracil (FU) infusion, followed by surgical resection. Instrumental restaging and routine histological examination, including tumor regression grading, were performed to asses the response to neoadjuvant therapy. RESULTS: The cCR rate corresponds to pCR rate, while a 3.5% of cPR and a 3.4% of cSD corresponded to a pPD. cPR and cSD show a PPV of 92.8% and 90.9% respectively, while cPD NPV is 20%. No case was found with no regression (grade 0). Tumor regression was defined grade 1 in 24.5% of cases, grade 2 was found in 58.5% of cases, 7.5% were grade 3, and 9.5% showed complete regression (grade 4). Pathologic response resulted to be associated with regression grade (p=0.006). Tumor regression grading is an independent variable for pT (p=0.0002), pN status (p=0.00004), pathologic staging (p=0.000001) and local recurrence (p=0.003). CONCLUSION: Our results lead us to consider only pathologic evaluation to determine the response to neoadjuvant treatment: the application of tumor regression grading on the specimens obtained after combined neoadjuvant chemoradiotherapy and surgery is useful to plan a better therapeutic strategy on the ground of a quantitative evaluation of the response to neoadjuvant treatment; it shows it is an important comparable pathological feature, useful in comparing different protocols' results and differences between patient's response as well as prognostic factors.


Asunto(s)
Antineoplásicos/uso terapéutico , Estadificación de Neoplasias/métodos , Neoplasias del Recto/diagnóstico , Adulto , Anciano , Biopsia , Colonoscopía , Progresión de la Enfermedad , Endosonografía , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Terapia Neoadyuvante , Neoplasias del Recto/tratamiento farmacológico , Neoplasias del Recto/radioterapia , Estudios Retrospectivos , Tomografía Computarizada por Rayos X , Resultado del Tratamiento
10.
Cancer Lett ; 212(2): 233-9, 2004 Aug 30.
Artículo en Inglés | MEDLINE | ID: mdl-15279903

RESUMEN

Galectins are a family of animal beta-galactoside-binding lectins involved in malignant transformation and progression. The present study evaluated the immunohistochemical expression of galectin-3 in a consecutive series of 81 radically resected non-small cell lung carcinomas (NSCLCs). The main pattern of galectin-3 expression was cytoplasmic (median percentage of cells with cytoplasmic positivity: 80.0%). The median percentage of tumor cells with nuclear and cytoplasmic co-expression of galectin-3 was 3.5%. No cases with exclusive nuclear immunostaining were observed. Functional interaction between galectin-3 and the thyroid transcription factor-1 (TTF-1) was previously demonstrated by cotransfection experiments. In the present study, concomitant expression of nuclear galectin-3 and TTF-1 was independently associated with a worse clinical outcome (HR 2.0; P = 0.01).


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Galectina 3/biosíntesis , Regulación Neoplásica de la Expresión Génica , Neoplasias Pulmonares/metabolismo , Adenocarcinoma/metabolismo , Adulto , Anciano , Carcinoma de Células Escamosas/metabolismo , Núcleo Celular/metabolismo , Transformación Celular Neoplásica , Citoplasma/metabolismo , Progresión de la Enfermedad , Femenino , Humanos , Inmunohistoquímica , Lectinas/metabolismo , Masculino , Persona de Mediana Edad , Proteínas Nucleares/biosíntesis , Factor Nuclear Tiroideo 1 , Factores de Transcripción/biosíntesis , Transcripción Genética
11.
Adv Clin Path ; 6(2): 105-10, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19753733

RESUMEN

AIMS: The aim of this case report is to present the pathological, clinical, and ethic problems due to the diagnosis of an adnexal mass in a female patient with an undetected androgen insensitivity syndrome. METHODS: We employed both commonly used pathologic techniques, such as hematoxylin-eosin staining and immunohystochemistry, both fluorescence in situ hybridization on paraffin-embedded tissue sections using probes for chromosomes X and Y. MAIN RESULTS: At pathologic evaluation, a diagnosis of Sertoli cell tumor was made. Fluorescence in situ hybridization showed an XY karyotype of tumor cells. The final diagnosis was bilateral Sertoli cell adenoma in a patient with testicular feminization syndrome. CONCLUSION: Androgen insensitivity syndrome is caused by insensitivity of end organs to androgen caused by a non-functioning receptor. The diagnosis of testicular feminization has been made as late as the ninth decade. In this case, two kinds of problem derived from the pathologist point of view: first, the demonstration of chromosomal sex to confirm the diagnosis, and second, the transfer of diagnosis to the patient and to the clinicians.


Asunto(s)
Síndrome de Resistencia Androgénica/patología , Neoplasias Ováricas/patología , Tumor de Células de Sertoli/patología , Anciano , Síndrome de Resistencia Androgénica/cirugía , Cromosomas Humanos X , Cromosomas Humanos Y , Femenino , Feminización , Humanos , Hibridación Fluorescente in Situ , Masculino , Epiplón/cirugía , Neoplasias Ováricas/cirugía , Ovariectomía , Tumor de Células de Sertoli/cirugía , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...